Do direct oral anticoagulants (DOACs) prevent recurrent VTE compared to low-molecular-weight heparin (LMWH) in patients with cancer associated thrombosis (CAT)?
In patients with cancer-associated thrombosis, DOACs are more effective than LMWHs for preventing recurrent VTE but carry a slightly higher absolute risk (2-3%) of major bleeding.
DOACs were more effective than LMWHs to prevent recurrent VTE but were associated with a significantly increased risk of major bleeding as well as a trend toward more CRNMB. The absolute risk differences were small (2-3%) for both primary outcomes and may reflect better compliance with DOACs than LMWHs.
Li et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: